1. Metabolic Enzyme/Protease
  2. Cytochrome P450
  3. Diosmetin

Diosmetin  (Synonyms: 香叶木素)

目录号: HY-N0125 纯度: 99.63%
COA 产品使用指南

Diosmetin是抑制人CYP1A酶活性的天然类黄酮, 在HepG2细胞的 IC50值为40 μM。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Diosmetin Chemical Structure

Diosmetin Chemical Structure

CAS No. : 520-34-3

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥550
In-stock
50 mg ¥500
In-stock
100 mg ¥700
In-stock
200 mg ¥981
In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Diosmetin:

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Diosmetin is a natural flavonoid which inhibits human CYP1A enzyme activity with an IC50 of 40 μM in HepG2 cell.

IC50 & Target

CYP1

 

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
HepG2 EC50
7.98 μM
Compound: Diosmetin
Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
[PMID: 26974372]
HT-22 EC50
59.7 μM
Compound: 12
Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay
Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay
[PMID: 32991171]
K562 IC50
8.42 μM
Compound: Diosmetin
Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay
[PMID: 35551036]
KBM5 IC50
6.46 μM
Compound: Diosmetin
Antiproliferative activity against human KBM5 cells harbouring T315I mutant assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay
Antiproliferative activity against human KBM5 cells harbouring T315I mutant assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay
[PMID: 35551036]
KBM5 IC50
8.52 μM
Compound: Diosmetin
Antiproliferative activity against human KBM5 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay
Antiproliferative activity against human KBM5 cells assessed as cell growth inhibition measured after 24 to 48 hrs by MTS assay
[PMID: 35551036]
Monocyte IC50
3 μM
Compound: diosmetin
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
[PMID: 8882428]
Neutrophil IC50
0.7 μM
Compound: 4g, Diosmetin
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay
[PMID: 23871908]
Neutrophil IC50
10.3 μM
Compound: 4g, Diosmetin
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay
[PMID: 23871908]
Neutrophil IC50
15 μM
Compound: 4g, Diosmetin
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
[PMID: 23871908]
Neutrophil IC50
3.6 μM
Compound: 4g, Diosmetin
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
[PMID: 23871908]
Peritoneal macrophage IC50
8.9 μM
Compound: 28; kp18
Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
[PMID: 27955927]
RAW264.7 CC50
> 100 μM
Compound: 19
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 33667099]
RAW264.7 IC50
16.7 μM
Compound: 28; kp18
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method
[PMID: 27955927]
RAW264.7 IC50
32.2 μM
Compound: 28; kp18
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method
Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Greiss method
[PMID: 27955927]
RAW264.7 IC50
34.5 μM
Compound: 19
Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay
Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay
[PMID: 33667099]
RAW264.7 IC50
8.4 μM
Compound: 10
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA
[PMID: 31747281]
体外研究
(In Vitro)

Diosmetin 以浓度依赖性方式抑制 HepG2 细胞的细胞增殖。未经处理的 HepG2 细胞生长良好,骨架正常,而经 Diosmetin 处理的细胞发生变形,部分细胞呈圆形漂浮状态[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

用 Diosmetin 预处理可显著降低淀粉酶和脂肪酶的血清水平;组织损伤;肿瘤坏死因子 (TNF)-α、白细胞介素 (IL)-1β 和 IL-6 的分泌;髓过氧化物酶 (MPO) 活性、胰蛋白酶原激活肽 (TAP) 水平、诱导型一氧化氮合酶 (iNOS) 的表达;和核因子 (NF)-κB 在雨蛙素诱导的急性胰腺炎中的激活[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

300.26

Formula

C16H12O6

CAS 号
性状

固体

颜色

Light yellow to yellow

中文名称

地奥司明EP杂质F)

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 100 mg/mL (333.04 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.3304 mL 16.6521 mL 33.3041 mL
5 mM 0.6661 mL 3.3304 mL 6.6608 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.33 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。

以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

  • 方案 一

    请依序添加每种溶剂: 0.5% CMC-Na/saline water

    Solubility: 10 mg/mL (33.30 mM); 悬浊液; 超声助溶

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料
参考文献
Cell Assay
[1]

Diosmetin is dissolved in DMSO which is maintained at a constant concentration in control samples (2%). HepG2 cells are maintained in a humidified atmosphere of 5% CO2 at 37°C, and cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin and 100 U/mL streptomycin. HepG2 cell density is adjusted to 2×104 cells/100 μL, and the cells are seeded into 96-well plates and placed in an incubator overnight (37°C in 5% CO2) to allow for attachment and recovery. MTT analyses are performed. Briefly, cells are pretreated with 5, 10, 15 and 20 μg/mL diosmetin for 24 h. A total of 20 μL MTT solution (5 mg/mL in PBS) solution is transferred to each well to yield a final 120 μL/well and to separate wells a total of 10 μL CCK8 (5 mg/mL in PBS) is transferred. The plates are incubated for 4 h at 37°C in 5% CO2 and the absorbance is recorded at wavelengths of 595 nm and 450 nm, respectively. The half maximal inhibitory concentration (IC50) of diosmetin is calculated[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Experimental acute pancreatitis is induced in mice by seven intraperitoneal injection of cerulein (50 μg/kg) at hourly intervals. Diosmetin (100 mg/kg) or vehicle is pretreated 2 h before the first cerulein injection. After 6 h, 9 h, 12 h of the first cerulein injection, the severity of acute pancreatitis is evaluated biochemically and morphologically[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.3304 mL 16.6521 mL 33.3042 mL 83.2604 mL
5 mM 0.6661 mL 3.3304 mL 6.6608 mL 16.6521 mL
10 mM 0.3330 mL 1.6652 mL 3.3304 mL 8.3260 mL
15 mM 0.2220 mL 1.1101 mL 2.2203 mL 5.5507 mL
20 mM 0.1665 mL 0.8326 mL 1.6652 mL 4.1630 mL
25 mM 0.1332 mL 0.6661 mL 1.3322 mL 3.3304 mL
30 mM 0.1110 mL 0.5551 mL 1.1101 mL 2.7753 mL
40 mM 0.0833 mL 0.4163 mL 0.8326 mL 2.0815 mL
50 mM 0.0666 mL 0.3330 mL 0.6661 mL 1.6652 mL
60 mM 0.0555 mL 0.2775 mL 0.5551 mL 1.3877 mL
80 mM 0.0416 mL 0.2082 mL 0.4163 mL 1.0408 mL
100 mM 0.0333 mL 0.1665 mL 0.3330 mL 0.8326 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Diosmetin
目录号:
HY-N0125
需求量: